PTCT - PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder | Benzinga
Thursday, PTC Therapeutics Inc (NASDAQ:PTCT) shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington’s disease (HD) patients.
HD is an inherited condition in which nerve cells in the brain break down over time, resulting in progressive movement, thinking (cognitive), and psychiatric symptoms.
At Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in the interim cohort of patients.
Related: PTC Therapeutics Says Interim Data For Huntington’s Disease Candidate ...